The global cancer immunotherapy market size was estimated at USD 153.27 billion in 2025 and is projected to reach USD 305.80 billion by 2033, growing at a CAGR of 9.02% from 2026 to 2033. The increasing prevalence of cancer is a significant factor driving market growth.
According to the American Cancer Society Journal, in the U.S., about 2 million new cancer cases and 611,720 cancer deaths are estimated to occur in the year 2024. Growing R&D activities by pharmaceutical companies, technological advancements, and the introduction of novel drugs are expected to drive the growth of the cancer immunotherapy industry in the forecast period. The increasing prevalence of cancer is boosting the demand for the cancer immunotherapy market. According to the International Agency for Research on Cancer (IARC) estimates, in the year 2020, there were about 19.29 million cancer cases, which is estimated to increase to 24.58 million cases by 2030. This significant increase in the disease burden on the population is expected to drive the market growth.
Rising approval of novel immunotherapies is expected to propel the market growth over the forecast period. For instance, in December 2024, AstraZeneca’s immunotherapy drug Imfinzi (durvalumab) became the first and only approved regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after platinum-based chemotherapy and radiation therapy. Similarly, the increasing patient preference for subcutaneous drug administration is fueling market growth. In September 2024, the FDA approved Tecentriq Hybreza, the first subcutaneous PD-(L)1 inhibitor, representing a significant breakthrough in cancer immunotherapy. This formulation offers patients a faster treatment option (7 minutes versus 30-60 minutes for intravenous infusion) while maintaining the same safety and efficacy as the intravenous version.
Various strategic initiatives undertaken by major players are also anticipated to facilitate the market demand. For instance, in September 2023, Immatics and Moderna strategically collaborated to develop the Oncology Therapeutics. The collaboration includes an assessment of Immatics' investigational PRAME203 TCRT in combination with the MARTE mRNA cancer vaccine being developed by Moderna. Moreover, in August 2023, FBD Biologics Limited and Shanghai Henlius Biotech, Inc. entered into a strategic collaboration to boost the development of new immunotherapies. These aspects are driving the market growth.
This product will be delivered within 1-3 business days.
According to the American Cancer Society Journal, in the U.S., about 2 million new cancer cases and 611,720 cancer deaths are estimated to occur in the year 2024. Growing R&D activities by pharmaceutical companies, technological advancements, and the introduction of novel drugs are expected to drive the growth of the cancer immunotherapy industry in the forecast period. The increasing prevalence of cancer is boosting the demand for the cancer immunotherapy market. According to the International Agency for Research on Cancer (IARC) estimates, in the year 2020, there were about 19.29 million cancer cases, which is estimated to increase to 24.58 million cases by 2030. This significant increase in the disease burden on the population is expected to drive the market growth.
Rising approval of novel immunotherapies is expected to propel the market growth over the forecast period. For instance, in December 2024, AstraZeneca’s immunotherapy drug Imfinzi (durvalumab) became the first and only approved regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed after platinum-based chemotherapy and radiation therapy. Similarly, the increasing patient preference for subcutaneous drug administration is fueling market growth. In September 2024, the FDA approved Tecentriq Hybreza, the first subcutaneous PD-(L)1 inhibitor, representing a significant breakthrough in cancer immunotherapy. This formulation offers patients a faster treatment option (7 minutes versus 30-60 minutes for intravenous infusion) while maintaining the same safety and efficacy as the intravenous version.
Various strategic initiatives undertaken by major players are also anticipated to facilitate the market demand. For instance, in September 2023, Immatics and Moderna strategically collaborated to develop the Oncology Therapeutics. The collaboration includes an assessment of Immatics' investigational PRAME203 TCRT in combination with the MARTE mRNA cancer vaccine being developed by Moderna. Moreover, in August 2023, FBD Biologics Limited and Shanghai Henlius Biotech, Inc. entered into a strategic collaboration to boost the development of new immunotherapies. These aspects are driving the market growth.
Global Cancer Immunotherapy Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. The report has segmented the global cancer immunotherapy market report based on product, application, distribution channel, end use, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- Monoclonal Antibodies
- Immunomodulators
- Oncolytic Viral Therapies and Cancer Vaccines
Application Outlook (Revenue, USD Million, 2021-2033)
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Head and Neck Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Others
Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals and Clinics
- Cancer Research Centers
- Others
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Cancer Immunotherapy Market Variables, Trends & Scope
Chapter 4. Cancer Immunotherapy Market: Product Estimates & Trend Analysis
Chapter 5. Cancer Immunotherapy Market: Application Estimates & Trend Analysis
Chapter 6. Cancer Immunotherapy Market: Distribution Estimates & Trend Analysis
Chapter 7. Cancer Immunotherapy Market: End Use Estimates & Trend Analysis
Chapter 8. Cancer Immunotherapy Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Cancer Immunotherapy market report include:- Pfizer Inc.
- AstraZeneca
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
- Novartis AG
- Lilly
- Johnson & Johnson Services, Inc.
- Immunocore, Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | December 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 153.27 Billion |
| Forecasted Market Value ( USD | $ 305.8 Billion |
| Compound Annual Growth Rate | 9.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
